EPC Enrichment and Enumeration Kit, human

EPC Enrichment and Enumeration Kit, human

The EPC Enrichment and Enumeration Kit is designed for the enumeration of circulating EPCs (cEPCs) from peripheral blood, cord blood, or leukapheresis products as well as EPCs from bone marrow. To ensure reliable enumeration results, the EPCs are enriched during the procedure to increase the sensitivity of the flow cytometric analysis.
The kit contains all reagents for:
  • red blood cell lysis,
  • EPC enrichment,
  • blocking of Fc receptor–mediated non-specific labeling of non-target cells,
  • enumeration of EPCs based on expression of CD34, CD133, and CD309,
  • exclusion of CD14+ cells,
  • exclusion of dead cells,
  • isotype controls.

Background information

Endothelial progenitor cells (EPCs) are defined by the expression of CD34, CD133, and CD309 (VEGFR-2/KDR)
1,2
and have been enumerated based on the expression of these markers by several studies. They are considered a measurable parameter for the assessment of risk factors for various diseases
3–5
as well as for the capacity for vascular repairing. cEPC numbers were correlated with, for example,
  • certain phases during congestive heart failure6 ,
  • acute myocardial infarction7 ,
  • risk factors for atherosclerosis5 ,
  • risk factors for cardiovascular disease8 ,
  • physical training9 ,
  • cessation of smoking10 .
The EPC Enrichment and Eunmeration Kit contains everything needed for EPC enrichment followed by enumeration with CD34, CD133/2, CD309, CD14 fluorochrome-conjugated monoclonal antibodies.

Columns

MS or MACSQuant
®
Columns.
  • Selected references

    1. Peichev, M. et al. (2000)
      Expression of VEGFR-2 and AC133 by circulating human CD34
      +
      cells identifies a population of functional endothelial precursors.
      Blood 95: 952-958
    2. Rafii, S. and Lyden, D. (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9: 702-712
    3. Hill, J. et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348: 593-600
    4. Urbich, C. and Dimmeler, S. (2005) Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int. 67: 1672-1676
    5. Werner, N. and Nickenig, G. (2006) Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler. Thromb. Vasc. Biol. 26: 257-266
    6. Valgimigli, M. et al. (2004)
      CD34
      +
      and endothelial progenitor cells in patients with various degrees of congestive heart failure.
      Circulation 110: 1209-1212
    7. Massa, M. et al. (2005) Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105: 199-206
    8. Vasa, M. et al. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89: e1-e7
    9. Steiner, S. et al. (2005) Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 181: 305-310
    10. Kondo, T. et al. (2004) Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler. Thromb. Vasc. Biol. 24: 1442-1447
  • Brochures and posters

  • Scientific posters

Product options: 1
for 20
tests
(1)
-

Related products

11 products available | view all